CapEdge
Loading...
Advanced
What's new? Log in Free sign up
  • Home
  • Sectors & IndustriesSectors
  • Earnings
  • IPOs
  • SPACs
  • Transcripts
  • Insider
  • Institutional
  • Crypto
  • Screeners
  • Reddit
  • Splits
  • ENTX Dashboard
  • Financials
  • Filings
  • Transcripts
  • Insider
  • Institutional
  • Shorts
  • News
  • Patents
  • Reddit

Entera Bio (ENTX)

Company Profile
Entera is a leader in the development of orally delivered large molecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company's proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company's most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc.
Entera Bio logo

Company profile

Ticker
ENTX, ENTXW
Exchange
NASDAQ
Website
www.enterabio.com
CEO
Adam Gridley
Employees
Incorporated
Israel
Location
Israel
Fiscal year end
Dec 31
Sector
Manufacturing > Biological Product (except Diagnostic) Manufacturing
Industry (SIC)
Biological Products, (No Diagnostic Substances)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Sana Biotechnology • Bio-Techne • Exelixis • Ginkgo Bioworks ...
SEC CIK
0001638097
Corporate docs
Articles of Incorporation & Bylaws
Underwriting Agreements
Plans of Reorganization
Indentures
Material Contracts & Credit Agreements
Subsidiaries Lists
Subsidiaries
Entera Bio Inc. ...

ENTX stock data

Latest filings (excl ownership)
View all
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
23 Nov 22
10-Q
2022 Q3
Quarterly report
10 Nov 22
8-K
Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022
10 Nov 22
8-K
Other Events
6 Oct 22
8-K
Submission of Matters to a Vote of Security Holders
9 Sep 22
424B5
Prospectus supplement for primary offering
2 Sep 22
8-K
Entry into a Material Definitive Agreement
2 Sep 22
10-Q
2022 Q2
Quarterly report
11 Aug 22
8-K
Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022
11 Aug 22
8-K
Entera Bio Corporate PresentationAugust 2022
1 Aug 22
Transcripts
View all
ENTX
Earnings call transcript
2022 Q1
18 May 22
ENTX
Earnings call transcript
2021 Q4
8 Mar 22
ENTX
Earnings call transcript
2021 Q2
16 Aug 21
ENTX
Earnings call transcript
2020 Q4
18 Mar 21
ENTX
Earnings call transcript
2020 Q3
19 Nov 20
ENTX
Earnings call transcript
2020 Q2
20 Aug 20
ENTX
Earnings call transcript
2020 Q1
21 May 20
ENTX
Earnings call transcript
2019 Q4
26 Mar 20
ENTX
Earnings call transcript
2019 Q3
21 Nov 19
ENTX
Earnings call transcript
2019 Q2
20 Aug 19
Latest ownership filings
View all
4
ROGER GARCEAU
4 Jan 23
4
GERALD M LIEBERMAN
4 Jan 23
4
Ron Mayron
4 Jan 23
4
GERALD M OSTROV
4 Jan 23
4
Yonatan Malca
4 Jan 23
4
Sean Ellis
4 Jan 23
SC 13G/A
CENTILLION FUND INC.
18 Nov 22
SC 13G/A
CENTILLION FUND INC.
18 Nov 22
SC 13G/A
CENTILLION FUND INC.
18 Nov 22
4
Dana Yaacov-Garbeli
15 Nov 22

Financial summary

Financial statements Chart ENTX financial data
Quarter (USD) Sep 22 Jun 22 Mar 22 Dec 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 21 Dec 20 Dec 19 Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Cash burn rate (est.) Burn method: Change in cash Burn method: Operating income Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 14.39 mm 14.39 mm 14.39 mm 14.39 mm 14.39 mm
Cash burn (monthly) 975.33 k 881.17 k 957.67 k 1.17 mm 399.33 k
Cash used (since last report) 4.24 mm 3.83 mm 4.17 mm 5.10 mm 1.74 mm
Cash remaining 10.15 mm 10.56 mm 10.22 mm 9.29 mm 12.65 mm
Runway (months of cash) 10.4 12.0 10.7 7.9 31.7

Beta Read what these cash burn values mean

Financial data from Entera Bio earnings reports.

Institutional ownership, Q3 2022

ENTX institutional ownership history Ownership history
8.3% owned by funds/institutions
13F holders Current Prev Q Change
Total holders 1 13 -92.3%
Opened positions 0 0
Closed positions 12 2 +500.0%
Increased positions 1 1 –
Reduced positions 0 5 EXIT
13F shares Current Prev Q Change
Total value 3.24 mm 9.72 mm -66.7%
Total shares 2.40 mm 6.06 mm -60.4%
Total puts 0.00 0.00
Total calls 0.00 152.90 k EXIT
Total put/call ratio – – –
Largest owners Shares Value Change
Centillion Fund 2.40 mm $3.24 mm +111.9%
Largest transactions Shares Bought/sold Change
Knoll Capital Management 0.00 -2.48 mm EXIT
Ra Capital Management 0.00 -2.35 mm EXIT
Centillion Fund 2.40 mm +1.27 mm +111.9%
Geode Capital Management 0.00 -17.60 k EXIT
Millennium Management 0.00 -16.87 k EXIT
Citadel Advisors 0.00 -12.66 k EXIT
Altium Wealth Management 0.00 -11.83 k EXIT
Virtu Financial 0.00 -10.88 k EXIT
PNC PNC Financial Services 0.00 -10.00 k EXIT
UBS UBS Group AG - Registered Shares 0.00 -7.40 k EXIT
Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

ENTX insider ownership history Insider history
Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Jan 23 Sean Ellis Stock Option (right to buy Ordinary Shares, par value NIS 0.0000769 per share Grant Acquire A No No 0.73 89,041 65.00 k 89,041
2 Jan 23 Yonatan Malca Stock Option Ordinary Shares, par value NIS 0.0000769 per share Grant Acquire A No No 0.73 89,041 65.00 k 89,041
2 Jan 23 Gerald M Ostrov Stock Option Ordinary Shares, par value NIS 0.0000769 per share Grant Acquire A No No 0.73 89,041 65.00 k 89,041
2 Jan 23 Ron Mayron Stock Option Ordinary Shares, par value NIS 0.0000769 per share Grant Acquire A No No 0.73 89,041 65.00 k 89,041
2 Jan 23 Lieberman Gerald M Stock Option Ordinary Shares, par value NIS 0.0000769 per share Grant Acquire A No No 0.73 89,041 65.00 k 89,041
Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

News

From Benzinga Pro
Why Oblong Shares Are Trading Higher By 59%; Here Are 20 Stocks Moving Premarket
4 Jan 23
Gainers Elys Game Technology, Corp. (NASDAQ: ELYS) shares rose 63.2% to $0.4201 in pre-market trading after dropping 8% on Tuesday. Elys Game Technology and Cloakbook were recently granted a license to commence sportsbook operations in Washington, D.C.
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
17 Nov 22
Gainers Fast Radius, Inc. (NASDAQ: FSRD) shares surged 106.3% to close at $0.21 on Wednesday after dipping around 48% on Tuesday. Fast Radius established a timeline for a Chapter 11 sale process.
Entera Bio And 2 Other Stocks Under $1 Insiders Are Aggressively Buying
16 Nov 22
The Dow Jones gained by over 50 points on Tuesday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Why Tattooed Chef Shares Dipped Around 15%; Here Are 95 Biggest Movers From Friday
14 Nov 22
Why Compass Shares Are Trading Higher By Over 56%? Here Are 63 Stocks Moving In Friday's Mid-Day Session
11 Nov 22
Finsight
Resources
  • Knowledgebase
  • Log In
  • Register
Company
  • About
  • Contact
  • Solutions
Products
  • Deal Roadshow
  • DealVDR
  • Evercall
  • Finsight.com
CapEdge
  • Earnings Calendar
  • Earnings Transcripts
  • EDGAR Filing Screener
  • IPO Calendar
  • Compliance
  • Privacy
  • Security
  • Terms
AngelList LinkedIn